Barclays PLC Sells 53,281 Shares of Biohaven Ltd. (NYSE:BHVN)

Barclays PLC lessened its holdings in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 27.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 142,787 shares of the company's stock after selling 53,281 shares during the period. Barclays PLC owned 0.21% of Biohaven worth $1,950,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Compass Financial Advisors LLC acquired a new stake in shares of Biohaven during the first quarter worth about $239,000. Artal Group S.A. bought a new position in shares of Biohaven during the 4th quarter worth approximately $6,940,000. New England Capital Financial Advisors LLC bought a new position in shares of Biohaven during the 4th quarter worth approximately $332,000. Quantum Private Wealth LLC bought a new position in shares of Biohaven during the 1st quarter worth approximately $312,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Biohaven by 2.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,047 shares of the company's stock worth $375,000 after acquiring an additional 667 shares during the period. Institutional investors own 97.77% of the company's stock.

Several research analysts have recently commented on BHVN shares. JPMorgan Chase & Co. reduced their target price on Biohaven from $27.00 to $24.00 and set an "overweight" rating for the company in a research note on Wednesday. BTIG Research boosted their price target on Biohaven from $24.00 to $28.00 in a research note on Monday, June 5th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $25.25.

Check Out Our Latest Report on Biohaven

Shares of BHVN opened at $19.23 on Friday. Biohaven Ltd. has a 12-month low of $5.54 and a 12-month high of $26.64. The business has a 50-day simple moving average of $22.69 and a two-hundred day simple moving average of $17.86. The stock has a market cap of $1.31 billion, a PE ratio of -2.59 and a beta of 1.11.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, July 31st. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.14). On average, equities research analysts expect that Biohaven Ltd. will post -5.02 EPS for the current year.

In related news, Director John W. Childs purchased 100,000 shares of the firm's stock in a transaction dated Friday, August 4th. The stock was bought at an average price of $19.78 per share, with a total value of $1,978,000.00. Following the completion of the purchase, the director now owns 1,925,118 shares in the company, valued at approximately $38,078,834.04. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 12.40% of the company's stock.

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases.

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Biohaven, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.

While Biohaven currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.